{
    "2018-05-25": [
        [
            {
                "time": "2018-09-03",
                "original_text": "Teva’s Fremanezumab Gets September Action Date from FDA",
                "features": {
                    "keywords": [
                        "Fremanezumab",
                        "FDA",
                        "action date"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-15",
                "original_text": "Barclays Raises Its 12-Month Target Price on Teva Stock",
                "features": {
                    "keywords": [
                        "Barclays",
                        "target price",
                        "Teva"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-05-08",
                "original_text": "A Brief Overview of Merck’s First-Quarter Performance",
                "features": {
                    "keywords": [
                        "Merck",
                        "first-quarter",
                        "performance"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-06",
                "original_text": "Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval",
                "features": {
                    "keywords": [
                        "GE",
                        "Wabtec",
                        "merge",
                        "J&J",
                        "Glaxo",
                        "HIV drug",
                        "EU approval"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "industrials",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}